Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Disorders of Erythrocytes01:27

Disorders of Erythrocytes

728
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
728
Hematopoiesis01:21

Hematopoiesis

4.9K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
4.9K
Erythropoiesis01:14

Erythropoiesis

3.9K
Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia,...
3.9K
Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

3.0K
The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
3.0K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

260
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
260
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

3.6K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
3.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis.

Blood·2026
Same author

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Distinct Longitudinal Patterns of Basal and Squamous Cell Carcinoma in Polycythemia Vera and Essential Thrombocythemia.

American journal of hematology·2026
Same author

Add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: a randomized phase 3 study.

The oncologist·2026
Same author

The lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat in myelofibrosis: results from a phase 1/2 study.

Blood advances·2026
Same author

Autoimmune and Inflammatory Diseases in Polycythemia Vera and Essential Thrombocythemia: Impact on Disease Outcomes and Comorbidities.

American journal of hematology·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
查看所有相关文章

相关实验视频

Updated: May 11, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K

多细胞血病真实性 多细胞血病真实性

Claire N Harrison1, Tiziano Barbui2, Prithviraj Bose3

  • 1Guy's and St Thomas' NHS Foundation Trust, London, UK. Claire.Harrison@gstt.nhs.uk.

Nature reviews. Disease primers
|April 17, 2025
PubMed
概括
此摘要是机器生成的。

多细胞血病真 (PV) 是一种由红细胞过多而表现出的骨髓增殖性瘤. JAK2V617F突变是诊断和预后的关键,其减少是一个新兴的治疗目标.

更多相关视频

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.2K
Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.4K

相关实验视频

Last Updated: May 11, 2025

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
07:24

A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy

1.7K
Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
05:23

Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload

Published on: March 14, 2017

19.2K
Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis
11:50

Ex vivo Mimicry of Normal and Abnormal Human Hematopoiesis

Published on: April 10, 2012

15.4K

科学领域:

  • 血液学 血液学 血液学
  • 在瘤学瘤学.
  • 遗传学 是一个遗传学.

背景情况:

  • 多细胞血病真 (PV) 是一种骨髓增殖性瘤.
  • 紫外线呈现出红细胞瘤,白细胞瘤和血栓细胞瘤.
  • 并发症包括血栓形成,出血,骨髓纤维化和爆发阶段转变.

研究的目的:

  • 审查PV中JAK2V617F突变的诊断和预后意义.
  • 讨论目前和新兴的PV治疗策略.
  • 为了突出JAK2V617F变体的等位基因频率作为潜在的治疗标.

主要方法:

  • 关于真菌多细胞血症的当前文献的综述.
  • 分析JAK2V617F突变在光伏诊断和管理中的作用.
  • 评估既有和新的治疗干预措施.

主要成果:

  • 在超过95%的PV患者中存在JAK2V617F突变,对诊断至关重要.
  • JAK2V617F变体的等位基因频率与预后和并发症风险相关.
  • 目前的治疗方法包括瘤切除术,阿司匹林和细胞减小剂,如氧尿素,干扰素和鲁克索利提尼布.

结论:

  • 在PV诊断和风险分层方面,JAK2V617F突变测试是必不可少的.
  • 减少JAK2V617F变体的等位基因频率是一个有前途的治疗目标.
  • 细胞减少剂的长期益处正在出现,可能会扩大它们在光伏管理中的使用.